ArticleScientific reports2017
Intrathoracic solitary fibrous tumor - an international multicenter study on clinical outcome and novel circulating biomarkers.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Perioperative Decision-Making for a Solitary Fibrous Tumor of the Pleura: Lessons from Two Cases and Current Evidence.Diagnostics (Basel, Switzerland) · 2026Article
- Effectiveness of classification and scoring systems in solitary fibrous tumor prognosis prediction.Pakistan journal of medical sciences · 2026Article
- Prognostic clinical and pathological factors in intrathoracic solitary fibrous tumors: A retrospective single-center study.Turk gogus kalp damar cerrahisi dergisi · 2025Article
- Risk factors for recurrent disease after resection of solitary fibrous tumor: a systematic review.Frontiers in surgery · 2024Review
- Surgery for Solitary Fibrous Tumors of the Pleura: A Review of the Available Evidence.Cancers · 2023Review
- Article
- Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond.Cancers · 2022Review
- Locally advanced malignant solitary fibrous tumour successfully treated with conversion chemotherapy, operation and postoperative radiotherapy: a case report.The Journal of international medical research · 2021Article
- Review
- Recurrent Solitary Fibrous Tumor in Intradural Extramedullary Space: Case Report and Review of the Literature.Case reports in oncological medicine · 2021Article
- Intrapulmonary solitary fibrous tumor with adenofibromatous pattern with features of pleomorphic high grade sarcoma-a case report and an overview of the differential diagnosis.Quantitative imaging in medicine and surgery · 2021Article
- Pleural Solitary Fibrous Tumors-A Retrospective Study on 45 Patients.Medicina (Kaunas, Lithuania) · 2020Article
- Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition.Scientific reports · 2020Article
- The role of molecular pathology in mediastinal sarcomas.Mediastinum (Hong Kong, China) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intrathoracic solitary fibrous tumor (SFT) is a rare disease. Radical resection is the standard of care. However, estimating prognosis and planning follow-up and treatment strategies remains challenging. Data were retrospectively collected by five international centers to explore outcome and biomarkers for predicting event-free-survival (EFS). 125 histological proven SFT patients (74 female; 59.2%; 104 benign; 83.2%) were analyzed. The one-, three-, five- and ten-year EFS after curative-intent surgery was 98%, 90%, 77% and 67%, respectively. Patients age (≥59 vs. <59 years hazard ratio (HR) 4.23, 95 confidence interval (CI) 1.56-11.47, p = 0.005), tumor-dignity (malignant vs. benign HR 6.98, CI 3.01-16.20, p <0.001), tumor-size (>10 cm vs. ≤10 cm HR 2.53, CI 1.10-5.83, p = 0.030), de Perrot staging (late vs. early HR 3.85, CI 1.65-8.98, p = 0.002) and resection margins (positive vs. negative HR 4.17, CI 1.15-15.17, p = 0,030) were associated with EFS. Furthermore, fibrinogen (elevated vs. normal HR 4.00, CI 1.49-10.72, p = 0.006) and the neutrophil-to-lymphocyte-ratio (NLR > 5 vs. < 5 HR 3.91, CI 1.40-10.89, p = 0.009) were prognostic after univariate analyses. After multivariate analyses tumor-dignity and fibrinogen remained as independent prognosticators. Besides validating the role of age, tumor-dignity, tumor-size, stage and resection margins, we identified for the first time inflammatory markers as prognosticators in SFT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.